Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19

NCT04390139 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
SARS-CoV 2
Adult Respiratory Distress Syndrome

Interventions

DRUG: XCEL-UMC-BETA
OTHER: Placebo

Sponsor

Banc de Sang i Teixits